Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments
- Exceeded expectations of NURTEC™ ODT (rimegepant) with net product revenue of $43.8 million for the first quarter of 2021, totaling $107.4 million in net product revenue since launch in March 2020
- Continued brand momentum for NURTEC ODT totaling more than 600,000 prescriptions from product launch to date, with more than 33,000 unique prescribers
- Advanced Neuroinnovation™ Platform with multiple Phase 3 studies results expected within the next year, and enrolled first patient in Phase 2/3 trial of oral zavegepant, prompting $100 million Royalty Pharma milestone payment
News provided by
Share this article
Share this article
As a result of an inadvertent error, the version of the earnings release Biohaven Pharmaceutical Holding Company Ltd. ( Biohaven ) issued before market open on May 10, 2021 (the Original Earnings Release ) included certain inaccurate financial and operational data
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Biohaven to Report First Quarter 2021 Financial Results and Recent Business Developments on May 10, 2021
News provided by
Share this article
Share this article
NEW HAVEN, Conn., April 28, 2021 /PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming first quarter 2021 earnings call and webcast, reporting financial results for the quarter ended March 31, 2021 and providing a review of recent accomplishments and anticipated upcoming milestones, on Monday May 10, 2021 at 8:30 a.m. ET.
To access the call, please dial 877-407-9120 (domestic) or 412-902-1009 (international). The conference call webcast and accompanying slide presentation can be accessed through the Investors section of Biohaven s website at www.biohavenpharma.com. To ensure a timely connection, it is recommended tha
Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT
- NURTEC® ODT achieved preliminary net product revenue of approximately $43.8 million for the first quarter of 2021
- Launch to date net product revenue for NURTEC ODT is approximately $107.4 million, with over 500,000 prescriptions filled since launch in March 2020
News provided by
Share this article
Share this article
NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the first quarter of 2021.
Based on preliminary unaudited financial information, the Company reported $43.8 million in net product revenue from sales of NURTEC ODT in the first quarter of 2021. Total prescriptions of NURTEC ODT from product launch to date (as of March 31, 2021) were o
Message :
Required fields
NEW HAVEN, Conn., April 7, 2021 /PRNewswire/ - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the first quarter of 2021.
Based on preliminary unaudited financial information, the Company reported $43.8 million in net product revenue from sales of NURTEC ODT in the first quarter of 2021. Total prescriptions of NURTEC ODT from product launch to date (as of March 31, 2021) were over 500,000, with over 30,000 unique prescribers.
The foregoing information reflects the Company s estimate with respect to net product revenue for NURTEC ODT based on currently available information which is preliminary and unaudited, is not a comprehensive statement of the Company s financial results and is subject to completion of the Company s financial closing pr
vimarsana © 2020. All Rights Reserved.